Présentation

KN2.1 WHO Director-General address to GVIRF

Margaret Chan

Keynote Address

Auteurs

Langues

  • Anglais

Année de publication

2014

Type

Présentation

Catégories

Organisations

GVIRF-2014

Cette ressource apparaît sur le Thème suivant:

Cette ressource est incluse dans le tableau suivant:

TitreAuteurAnnéeTypeLangue
*Global Vaccine and Immunization Research Forum: Opportunities and challenges in vaccine discovery, development, and deliveryAndrew Ford, Angela Hwang, B. Fenton Hall, Joachim Hombach, Nancy Touchette2016Journal articleAnglais
Agenda - GVIRF 2014GVIRF Secretariat2014PresentationAnglais
KN1 Opening Session and KeynoteAnthony Fauci2014ReportAnglais
KN1.1 Vaccine Research and Development: Challenges and OpportunitiesAnthony Fauci2014PresentationAnglais
KN1.2 R&D in the "Decade of Vaccines"B. Fenton Hall2014PresentationAnglais
KN1.3 GVIRF Overview and GoalsJoachim Hombach2014PresentationAnglais
KN1.4 What do we expect from the meeting?José Esparza2014PresentationAnglais
KN2 Research for Universal Health Coverage; Perspective on Vaccines and Poverty ReductionMargaret Chan, Tim Evans2000ReportAnglais
KN2.1 WHO Director-General address to GVIRFMargaret Chan2014PresentationAnglais
KN2.2 Perspectives on Vaccines and Poverty ReductionT. Evans, World Bank2014PresentationAnglais
KN3 Importance of Innovation in Addressing Global Health Gaps in the Developing WorldTrevor MundelReportAnglais
KN3-1 The Importance of Innovation in Addressing Global Health Gaps in the Developing WorldTrevor MundelPresentationAnglais
P1a.1 Status of HIV Vaccine Research & DevelopmentWayne Koff2014PresentationAnglais
P1a.2 Progress towards the development of an HIV vaccine: DiscussionJosé Esparza2014PresentationAnglais
P1b Develop New and Improved Vaccines - TBCharles Mgone, Tom Evans, Uli Fruth2014ReportAnglais
P1b.1 Update on Tuberculosis Vaccines - 2014Tom Evans2014PresentationAnglais
P1b.2 TB Vaccine Development: Challenges & OpportunitiesUli Fruth2014PresentationAnglais
P1c Develop New and Improved Vaccines - MalariaAshley Birkett, Charles Mgone, Peter Smith2014ReportAnglais
P1c.1 Progress towards the development of a malaria vaccineAshley Birkett2014PresentationAnglais
P1c.2 Progress towards the development of a malaria vaccine: discussionPeter Smith2014PresentationAnglais
P2 Regulatory and Public Health Challenges for Vaccines Inducing Modest EfficacyDavid Salisbury2014ReportAnglais
P2.1 Regulatory and public health challengesPeter Smith2014PresentationAnglais
P2.2 Regulatory Considerations for Determining Vaccine EfficacyMarion Gruber2014PresentationAnglais
P3 Developing Next Generation Vaccines: Defining the Improvements Needed and Evaluating Their PotentialK. Neuzil2014ReportAnglais
P3.1 Developing next generation vaccines: IntroductionKathleen Neuzil2014PresentationAnglais
P3.2 Developing Country Vaccine Manufacturers - Access to ImmunizationUmesh Parashar2014PresentationAnglais
P3.3 Developing Next Generation Rotavirus Vaccines: Prospects from the Pipeline to Address Remaining Public Health NeedsMary K. Estes2014PresentationAnglais
P3.4 Evaluation of the Next Generation of Rotavirus VaccinesKathleen Neuzil2014PresentationAnglais
P5 Research to improve monitoring and evaluation of immunization programsJean-Marie Okwo-Bele2014ReportAnglais
P5.1 Immunization Registries in Latin America and the CaribbeanM. Carolina Danovaro-Holliday2014PresentationAnglais
P5.2 Influenza Vaccine Use in the Americas: Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-1Alba María Ropero-Álvarez2014PresentationAnglais
P6 Protection of pregnant women, neonates and infants by maternal immunizationHelen Rees2014ReportAnglais
P6.1 Public Health Benefits of Maternal ImmunizationKeith Klugman2014PresentationAnglais
P6.2 Maternal Immunization: which impact on infant immunity?Claire-Anne Siegrist2014PresentationAnglais
P7 Innovative vaccine research: the point of view of industry and biotech companiesMichael Mowatt, Odile LeroyReportAnglais
P7.1 Innovation for vaccines against poverty diseases: the need for new support mechanismsMartin Friede2014PresentationAnglais
P8 General ConclusionB. Fenton Hall, Chris Wilson, Jean-Marie Okwo-Bele2014ReportAnglais
W1 Towards the Development of a Universal Influenza VaccineDavid Spiro2014ReportAnglais
W1.1 Towards the Development of a Universal Influenza VaccineDavid Spiro2014PresentationAnglais
W2 Preferred Product Characteristics (PPC) as a Way to Guide Development of Products of High Public Health UtilityA. A. Adeyemo2014ReportAnglais
W2.1 WHO Preferred Product Characteristics: Bridging Vaccine R&D with Public HealthVasee Moorthy2014PresentationAnglais
W2.2 RSV Vaccine Development for Low and Middle Income Countries: Challenges and ProgressClaudio Lanata2014PresentationAnglais
W2.3 Group A streptococcal vaccines: Challenges and progressFlorian Schödel2014PresentationAnglais
W3.1 Leishmania Vaccine Development: Progress and challenges in the context of other control strategiesFarrokh Modabber2014PresentationAnglais
W3.2 Pre-exposure rabies vaccination (PreP) in children of endemic countriesD. Briggs2014PresentationAnglais
W4 How to Optimize Immunization Coverage? A case study from Measles-Rubella vaccinationA. A. Adeyemo2014ReportAnglais
W4.1 Progress, Challenges, and Lessons Learned in Achieving Measles and Rubella GoalsThomas Cherian2014PresentationAnglais
W4.2 Prioritizing the Research Agenda for Measles and RubellaWilliam Moss2014PresentationAnglais
W5.1 Immunization implementation research priority settingJohn Clemens2014PresentationAnglais
W5.2 Factors influencing community health volunteers in participating in health programs in AfricaFadima YAYA BOCOUM2014PresentationAnglais
Log in to vote

Ajouté par: Angela Hwang

Ajouté le: 2022-08-07 02:05:42

Consultations: 1992

Fichier téléchargé

KN2-1Chan.pdf

Cliquez pour télécharger

Signaler un problème

Ajouter une ressource